 Having reviewed the additional studies, the EMA Committee for Medicinal Products for Veterinary Use (CVMP) recommended granting marketing authorisation of pradofloxacin by consensus in February 2011.Marketing authorisation of pradofloxacin was granted by the European Commission in April 2011.The primary mode of action of fluoroquinolones involves interaction with enzymes essential for major DNA functions such as replication, transcription and recombination.